These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12429175)

  • 1. Dendritic cell-tumor cell fusion and staphylococcal enterotoxin B treatment in a pancreatic tumor model.
    McConnell EJ; Pathangey LB; Madsen CS; Gendler SJ; Mukherjee P
    J Surg Res; 2002 Oct; 107(2):196-202. PubMed ID: 12429175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mice with spontaneous pancreatic cancer naturally develop MUC-1-specific CTLs that eradicate tumors when adoptively transferred.
    Mukherjee P; Ginardi AR; Madsen CS; Sterner CJ; Adriance MC; Tevethia MJ; Gendler SJ
    J Immunol; 2000 Sep; 165(6):3451-60. PubMed ID: 10975866
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironment.
    Mukherjee P; Ginardi AR; Madsen CS; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    Glycoconj J; 2001; 18(11-12):931-42. PubMed ID: 12820727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice.
    Tanaka Y; Koido S; Chen D; Gendler SJ; Kufe D; Gong J
    Clin Immunol; 2001 Nov; 101(2):192-200. PubMed ID: 11683578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucin 1-specific immunotherapy in a mouse model of spontaneous breast cancer.
    Mukherjee P; Madsen CS; Ginardi AR; Tinder TL; Jacobs F; Parker J; Agrawal B; Longenecker BM; Gendler SJ
    J Immunother; 2003; 26(1):47-62. PubMed ID: 12514429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive immunotherapy for pancreatic cancer using MUC1 peptide-pulsed dendritic cells and activated T lymphocytes.
    Kondo H; Hazama S; Kawaoka T; Yoshino S; Yoshida S; Tokuno K; Takashima M; Ueno T; Hinoda Y; Oka M
    Anticancer Res; 2008; 28(1B):379-87. PubMed ID: 18383873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine.
    Rong Y; Jin D; Wu W; Lou W; Wang D; Kuang T; Ni X; Qin X
    BMC Cancer; 2009 Jun; 9():191. PubMed ID: 19534821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1.
    Kawaoka T; Oka M; Takashima M; Ueno T; Yamamoto K; Yahara N; Yoshino S; Hazama S
    Oncol Rep; 2008 Jul; 20(1):155-63. PubMed ID: 18575732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.
    Wang B; Zhu Y; Zhang JJ; Chen Z; Liang WB; Xu ZK
    Asian Pac J Cancer Prev; 2011; 12(11):2811-7. PubMed ID: 22393946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of anti-tumor immunity by high levels of Th1 and Th17 with a combination of dendritic cell fusion hybrids and regulatory T cell depletion in pancreatic cancer.
    Yamamoto M; Kamigaki T; Yamashita K; Hori Y; Hasegawa H; Kuroda D; Moriyama H; Nagata M; Ku Y; Kuroda Y
    Oncol Rep; 2009 Aug; 22(2):337-43. PubMed ID: 19578774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human dendritic cells transfected with amplified MUC1 mRNA stimulate cytotoxic T lymphocyte responses against pancreatic cancer in vitro.
    Chen J; Li HY; Wang D; Zhao JJ; Guo XZ
    J Gastroenterol Hepatol; 2011 Oct; 26(10):1509-18. PubMed ID: 21950745
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Dendritic cell-tumor cell fusion vaccine prevents growth of subcutaneous transplanted esophageal carcinomas].
    Deng YJ; Zhang LJ; Su XD; Zhang DK; Rong TH; Wang QJ; Xia JC
    Ai Zheng; 2009 Oct; 28(10):1067-71. PubMed ID: 19799815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxic T cell responses are enhanced by antigen design involving the presentation of MUC1 peptide on cholera toxin B subunit.
    Lu W; Qiu L; Yan Z; Lin Z; Cao M; Hu C; Wang Z; Wang J; Yu Y; Cheng X; Cao P; Li R
    Oncotarget; 2015 Oct; 6(33):34537-48. PubMed ID: 26417929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice.
    Koido S; Tanaka Y; Chen D; Kufe D; Gong J
    J Immunol; 2002 Mar; 168(5):2111-7. PubMed ID: 11859096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adoptive immunotherapy with MUC1-mRNA transfected dendritic cells and cytotoxic lymphocytes plus gemcitabine for unresectable pancreatic cancer.
    Shindo Y; Hazama S; Maeda Y; Matsui H; Iida M; Suzuki N; Yoshimura K; Ueno T; Yoshino S; Sakai K; Suehiro Y; Yamasaki T; Hinoda Y; Oka M
    J Transl Med; 2014 Jun; 12():175. PubMed ID: 24947606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
    Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
    Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of invasive transitional cell bladder carcinoma in immune intact human MUC1 transgenic mice: a model for immunotherapy development.
    Vang DP; Wurz GT; Griffey SM; Kao CJ; Gutierrez AM; Hanson GK; Wolf M; DeGregorio MW
    J Vis Exp; 2013 Oct; (80):e50868. PubMed ID: 24300078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selection and characterization of MUC1-specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells.
    Gong J; Apostolopoulos V; Chen D; Chen H; Koido S; Gendler SJ; McKenzie IF; Kufe D
    Immunology; 2000 Nov; 101(3):316-24. PubMed ID: 11106934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.
    Chen D; Xia J; Tanaka Y; Chen H; Koido S; Wernet O; Mukherjee P; Gendler SJ; Kufe D; Gong J
    Immunology; 2003 Jun; 109(2):300-7. PubMed ID: 12757626
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells.
    Tanaka Y; Koido S; Ohana M; Liu C; Gong J
    J Immunol; 2005 Feb; 174(3):1274-80. PubMed ID: 15661883
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.